newsfilter
← Latest News
GlobeNewswire·

KemPharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of "Higher-Dose SDX"

Data reveal serdexmethylphenidate (SDX) delivered at doses higher than those studied with AZSTARYS® is well-tolerated, yields dose-proportional d-MPH exposure, and produces targeted biological effects CELEBRATION, Fla., Dec. 14, 2021 (GLOBE NEWSW